Weekly Investment Analysts’ Ratings Changes for Natera (NTRA)

Natera (NASDAQ: NTRA) has recently received a number of price target changes and ratings updates:

• 10/13/2026 – Natera had its price target raised by TD Cowen from $340.00 to $480.00. They now have a “buy” rating on the stock.
• 10/12/2026 – Natera had its price target raised by Morgan Stanley from $355.00 to $435.00. They now have an “overweight” rating on the stock.
• 10/7/2026 – Natera had its price target raised by Barclays PLC from $340.00 to $475.00. They now have an “overweight” rating on the stock.
• 10/6/2026 – Natera had its price target raised by Citigroup Inc. from $365.00 to $480.00. They now have a “buy” rating on the stock.
• 10/1/2026 – Natera had its price target raised by Guggenheim from $360.00 to $475.00. They now have a “buy” rating on the stock.
• 9/25/2026 – Natera had its price target raised by Royal Bank Of Canada from $350.00 to $460.00. They now have an “outperform” rating on the stock.
• 9/9/2026 – Natera had its price target raised by UBS Group AG from $290.00 to $435.00. They now have a “buy” rating on the stock.
• 9/8/2026 – Natera is now covered by Rothschild & Co Redburn. They set a “buy” rating and a $385.00 price target on the stock.
• 9/8/2026 – Natera was upgraded by Royal Bank Of Canada from “outperform” to “buy”.
• 9/8/2026 – Natera is now covered by Rothschild & Co Redburn. They set a “buy” rating and a $385.00 price target on the stock.

Insider Buying and Selling at Natera

In related news, insider Solomon Moshkevich sold 15,160 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $326.89, for a total transaction of $4,955,652.40. Following the completion of the sale, the insider directly owned 110,859 shares in the company, valued at approximately $36,238,698.51. The trade was a 12.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Chapman sold 3,580 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $254.07, for a total transaction of $909,570.60. Following the sale, the chief executive officer directly owned 102,973 shares of the company’s stock, valued at approximately $26,162,350.11. This represents a 3.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 52,985 shares of company stock worth $16,119,137 over the last quarter. Company insiders own 5.05% of the company’s stock.

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to assess genetic and disease-related risks. The company uses technologies including cell-free DNA analysis and next-generation sequencing to support clinical decision-making in reproductive health, oncology and organ transplantation.

Its reproductive health offerings include Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test that evaluates whether prospective parents carry genetic variants associated with inherited disorders.